Effectiveness of a differentiated approach to the treatment of patients with polycystic ovary syndrome using inositols and combined oral contraceptives in early reproductive age
- 作者: Khashchenko E.P.1, Nadzharyan A.G.2, Uvarova E.V.1,3
-
隶属关系:
- Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
- M.V. Lomonosov Moscow State University
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- 期: 编号 3 (2021)
- 页面: 154-166
- 栏目: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249114
- DOI: https://doi.org/10.18565/aig.2021.3.154-166
- ID: 249114
如何引用文章
详细
全文:
作者简介
Elena Khashchenko
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: khashchenko_elena@mail.ru
PhD, senior researcher, 2nd Gynecological Department (children and adolescent gynecology)
Ani Nadzharyan
M.V. Lomonosov Moscow State University
Email: ani_nad@list.ru
student of the Faculty of Fundamental Medicine
Elena Uvarova
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
Email: elena-uvarova@yandex.ru
Dr. Med. Sci., Professor, Head of the 2nd Gynecological Department (children and adolescent gynecology); Professor of the Department of Obstetrics, Gynecology, Perinatology and Reproductology, Institute of Professional Education
参考
- Teede H.J., Misso M.L., Costello M.F., Dokras A., Laven J., Moran L. et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil. Steril. 2018; 110(3): 364-79. https://dx.doi.org/10.1016/j.fertnstert.2018.05.004.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil. Steril. 2004; 81(1): 19-25. https:// dx.doi.org/10.1016/j.fertnstert.2003.10.004.
- Хащенко Е.П., Уварова Е.В., Мамедова Ф.Ш. Фенотипические особенности синдрома поликистозных яичников у девочек подросткового возраста. Репродуктивное здоровье детей и подростков. 2017; 1: 37-50. [Khashchenko E.P., Uvarova E.V., Mamedova F.Sh. Phenotypic features of polycystic ovary syndrome in adolescent girls. Reproductive health of children and adolescents. 2017; 1: 37-50. (in Russian)].
- Legro R.S., Arslanian S.A., Ehrmann D.A., Hoeger K.M., Murad M.H., Pasquali R. et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 2013; 98(12): 4565-92. https://dx.doi.org/10.1210/jc.2013-2350.
- Fenton C., Wellington K., Moen M.D., Robinson D.M. Drospirenone/ ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris. Drugs. 2007; 67(12): 1749-65. https://dx.doi.org/10.2165/ 00003495-200767120-00007.
- Bhattacharya S.M., Jha A., DasMukhopadhyay L. Comparison of two contraceptive pills containing drospirenone and 20 |ig or 30 |ig ethinyl estradiol for polycystic ovary syndrome. Int. J. Gynaecol. Obstet. 2016; 132(2): 210-3. https://dx.doi.org/10.1016/j.ijgo.2015.06.065.
- Vitek W., Hoeger K.M. Treatment of polycystic ovary syndrome in adolescence. Semin. Reprod. Med. 2014; 32(3): 214-21. https:// dx.doi.org/10.1055/s-0034-1371093.
- Bachmann G., Kopacz S. Drospirenone/ethinyl estradiol 3 mg/20 mug (24/4 day regimen): hormonal contraceptive choices - use of a fourth-generation progestin. Patient Prefer. Adherence. 2009; 3: 259-64. https://dx.doi.org/10.2147/ ppa.s3901.
- Kouzi S.A., Yang S., Nuzum D.S., Dirks-Naylor A.J. Natural supplements for improving insulin sensitivity and glucose uptake in skeletal muscle. Front. Biosci. (Elite Ed). 2015; 7: 94-106.
- Genazzani A.D., Shefer K., Della Casa D., Prati A., Napolitano A., Manzo A. et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J. Endocrinol. Invest. 2018; 41(5): 583-90. https://dx.doi.org/10.1007/s40618-017-0782-z.
- Genazzani A.D., Despini G., Santagni S., Prati A., Rattighieri E., Chierchia E. et al. Effects of a combination of alpha lipoic acid and myo-inositol on insulin dynamics in overweight/obese patients with PCOS. Endocrinol. Metab. Synd. 2014; 3: 3. https://dx.doi.org/10.4172/2161-1017.1000140.
- Rago R., Marcucci I., Leto G., Caponecchia L., Salacone P., Bonanni P. et al. Effect of myo-inositol and alpha-lipoic acid on oocyte quality in polycystic ovary syndrome non-obese women undergoing in vitro fertilization: a pilot study. J. Biol. Regul. Homeost. Agents. 2015; 29(4): 913-23.
- Morgante G., Cappelli V., Di Sabatino A., Massaro M.G., De Leo V. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association. Minerva Ginecol. 2015; 67(5): 457-63.
- Cianci A., Panella M., Fichera M., Falduzzi C., Bartolo M., Caruso S. D-chiro-inositol and alpha lipoic acid treatment of metabolic and menses disorders in women with PCOS. Gynecol. Endocrinol. 2015; 31(6): 483-6. https:// dx.doi.org/10.3109/09513590.2015.1014784.
- Masharani U., Gjerde C., Evans J.L., Youngren J.F., Goldfine I.D. Effects of controlled-release alpha lipoic acid in lean, nondiabeticpatients with polycystic ovary syndrome. J. Diabetes Sci. Technol. 2010; 4(2): 359-64. https:// dx.doi.org/10.1177/193229681000400218.
- Bene J., Hadzsiev K., Melegh B. Role of carnitine and its derivatives in the development and management of type 2 diabetes. Nutr. Diabetes. 2018; 8(1): 8. https://dx.doi.org/10.1038/s41387-018-0017-1.
- Pekala J., Patkowska-Sokola B., Bodkowski R., Jamroz D., Nowakowski P., Lochynski S. et al. L-carnitine-metabolic functions and meaning in humans life. Curr. Drug Metab. 2011; 12(7): 667-78. https://dx.doi.org/ 10.2174/138920011796504536.
- Salehpour S., Nazari L., Hoseini S., Moghaddam P.B., Gachkar L. Effects of L-carnitine on polycystic ovary syndrome. JBRA Assist. Reprod. 2019; 23(4): 392-5. https://dx.doi.org/10.5935/1518-0557.20190033.
- Samimi M., Jamilian M., Ebrahimi F.A., Rahimi M., Tajbakhsh B., Asemi Z. Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin. Endocrinol. (Oxf). 2016; 84(6): 851-7. https:// dx.doi.org/10.1111/cen.13003.
- El Sharkwy I., Sharaf El-Din M. l-carnitine plus metformin in clomiphene-resistant obese PCOS women, reproductive and metabolic effects: a randomized clinical trial. Gynecol. Endocrinol. 2019; 35(8): 701-5. https://dx.doi.org/10.10 80/09513590.2019.1576622.
- Ismail A.M., Hamed A.H., Saso S., Thabet H.H. Adding L-carnitine to clomiphene resistant PCOS women improves the quality of ovulation and the pregnancy rate. A randomized clinical trial. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014; 180: 148-52. https://dx.doi.org/10.1016/j.ejogrb.2014.06.008.
- Vigerust N.F., Bohov P., Bjorndal B., Seifert R., Nygard O., Svardal A. et al. Free carnitine and acylcarnitines in obese patients with polycystic ovary syndrome and effects of pioglitazone treatment. Fertil. Steril. 2012; 98(6): 1620-6. e1. https://dx.doi.org/10.1016/j.fertnstert.2012.08.024.
- Fenkci S.M., Fenkci V., Oztekin O., Rota S., Karagenc N. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome. Hum. Reprod. 2008; 23(7): 1602-6. https://dx.doi.org/10.1093/humrep/den109.
- Lagana A.S., Garzon S., Casarin J., Franchi M., Ghezzi F. Inositol in polycystic ovary syndrome: restoring fertility through a pathophysiology-based approach. Trends Endocrinol. Metab. 2018; 29(11): 768-80. https://dx.doi.org/10.1016/ j.tem.2018.09.001.
- Zeng L., Yang K. Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2018; 59(1): 30-8. https:// dx.doi.org/10.1007/s12020-017-1442-y.
- Facchinetti F., Orru B., Grandi G., Unfer V. Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a metaanalysis of randomized clinical trials. Gynecol. Endocrinol. 2019; 35(3): 198206. https://dx.doi.org/10.1080/09513590.2018.1540578.
- Pundir J., Psaroudakis D., Savnur P., Bhide P., Sabatini L., Teede H. et al. Inositol treatment of anovulation in women with polycystic ovary syndrome: a metaanalysis of randomised trials. BJOG. 2018; 125(3): 299-308. https://dx.doi. org10.1111/1471-0528.14754.
- Pkhaladze L., Barbakadze L., Kvashilava N. Myo-inositol in the treatment of teenagers affected by PCOS. Int. J. Endocrinol. 2016; 2016: 1473612. https:// dx.doi.org/10.1155/2016/1473612.